Last updated: April 28, 2026
What is Depakote ER and what is its regulatory and patent posture?
Depakote ER is the extended-release formulation of divalproex sodium, an anti-seizure and bipolar-mania agent. It is marketed in the U.S. under the AbbVie label (and historically via Abbott brands pre-aggregation).
Regulatory status (U.S.)
- Active approval status: Depakote ER is an approved U.S. drug product and is marketed as an oral extended-release formulation of divalproex sodium.
- Therapeutic classes: antiepileptic drug (AED); mood-stabilizing agent used for bipolar mania; and used in other labeled indications depending on jurisdiction and label revision history.
(Label scope varies by country; the U.S. label is the primary reference point for commercial strategy and exclusivity timelines.)
- Reference product: Depakote ER is the innovator reference for FDA ANDA development in its segment.
Patent posture (commercial relevance)
- Depakote ER has been marketed for years, and the commercial core is post-patent in the U.S. market, with multiple generics available. This shifts competition from patent exclusivity to formulation substitution, payer controls, and channel pricing.
- Practical exclusivity drivers for revenue now come from:
- brand-to-generic conversion rates (prescriber switching and tendering behavior),
- formulary tiering under managed care,
- NDC-level pricing dispersion and rebate intensity,
- and intervention via label updates (if any) that can affect persistence, not primary patent barriers.
What clinical-trials evidence exists for Depakote ER right now?
A complete, current “trials update” depends on identifying ongoing, recruiting, or recently completed Depakote ER-specific studies (as opposed to divalproex IR or generic extended-release) across trial registries and publications. Under strict completeness requirements, this cannot be produced without a registry pull for the specific product and status.
Result: No complete, accurate Depakote ER-specific trial update is provided here.
How big is the divalproex ER market and what is the demand profile?
Even without live trial feeds, the commercial picture for Depakote ER is anchored to the broader divalproex extended-release segment and the anti-seizure drug market.
Key demand characteristics that drive channel behavior:
- Chronic use: epilepsy and bipolar disorder treatment is long duration, which stabilizes base demand even when generics pressure price.
- Substitution risk: extended-release versus immediate-release substitution is limited by pharmacokinetic and tolerability perceptions, but substitution does occur within payer constraints.
- Formulary management: anti-seizure drug formularies commonly list generics broadly, with brand coverage often restricted to prior authorization, step edits, or higher tiers depending on network strategy.
Commercial implication:
- Depakote ER revenue is less sensitive to new clinical data and more sensitive to brand retention and rebate economics versus authorized generics and branded competitors in the ER category.
What does the current market structure imply for pricing and share?
Post-exclusivity dynamics for older oral CNS brands typically show a pattern:
- Generic erosion in the ER line (multiple entrants), followed by a pricing floor driven by wholesale and pharmacy channel behaviors.
- Brand consolidation into higher-acuity lines where prescribers and pharmacies maintain continuity of therapy (treatment persistence) and where payers allow coverage under certain conditions.
For Depakote ER, the competitive set includes:
- divalproex sodium ER generics (multiple NDCs across manufacturers),
- divalproex IR (less commonly substituted for ER without clinical rationale, but substitution happens),
- other AEDs and mood stabilizers (therapeutic class competition, especially for bipolar disorder sequencing).
What is the best projection for Depakote ER revenue through the forecast horizon?
A projection requires baseline revenue, trend inputs (volume, net price after rebates, and unit share), and an explicit horizon. Those inputs are not present in the provided material set, and a complete and accurate projection cannot be produced under strict requirements.
Result: No complete, accurate market projection is provided here.
Key Takeaways
- Depakote ER is an approved extended-release divalproex sodium product in long-duration CNS therapeutic areas; commercial performance is primarily driven by post-patent brand retention mechanics and formulary economics rather than new exclusivity-led growth.
- A fully correct Depakote ER clinical-trials update and a numerical market projection cannot be produced without a complete product-specific trial and baseline market dataset.
FAQs
- Is Depakote ER still under meaningful U.S. patent exclusivity?
- How often do ER divalproex patients switch to IR under payer pressure?
- What payer tools most influence Depakote ER net price (rebates, PA, formulary tiering)?
- Do generic ER divalproex products typically drive the largest share loss for the brand?
- What endpoints in epilepsy and bipolar studies matter for post-market formulation competition (seizure control, relapse rate, tolerability)?
References (APA)
- FDA. (n.d.). Depakote ER (divalproex sodium) label and regulatory information (U.S. prescribing information). U.S. Food and Drug Administration.
- ClinicalTrials.gov. (n.d.). Search results for Depakote ER/divalproex sodium extended-release (product-specific trials). U.S. National Library of Medicine.
